Instead of marketing the drug to patients and individual physicians, Novartis will attempt to convince health system executives that large-scale rollouts of the drug could prevent thousands of heart attacks and strokes. Using EHR records, Novartis would work with health systems to identify heart patients who have trouble controlling their cholesterol with existing drugs and offer them Leqvio instead.
The drugmaker said it plans to approach about 200 health systems nationwide with this agreement offer once the FDA finalizes its review of Leqvio early next year.
Novartis acquired Leqvio during its $9.7 billion acquisition of the Medicines Co., a deal that was finalized in January 2020. Unlike most cholesterol drugs, which entail a daily pill, Leqvio is administered twice a year via an injection.
View the full article here.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
